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Background: Liver metastases from breast cancer (LMBC) are typically considered to indicate systemic disease
spread and patients are most often offered systemic palliative treatment only. However, retrospective studies
suggest that some patients may have improved survival with local treatment of their liver metastases compared to
systemic therapy alone. In the absence of randomized trials, it is important to identify patient characteristics
indicating that benefit from local treatment can be expected.
Methods: 59 patients undergoing radiofrequency ablation (RFA), interstitial brachytherapy (BT), or
radioembolization (RE) of LMBC as a salvage treatment were studied. Potential factors influencing survival were
analyzed in a multivariate Cox model. For factors identified to have an independent survival impact, Kaplan-Meier
analysis and comparison of overall survival (OS) using the log-rank test was performed.
Results: Median OS following local interventional treatment was 21.9 months. Considering only factors evaluable at
treatment initiation, maximum diameter of liver metastases (≥3.9 cm; HR: 3.1), liver volume (≥ 1376 mL; HR: 2.3),
and history of prior chemotherapy (≥ 3 lines of treatment; HR: 2.5-2.6) showed an independent survival impact.
When follow-up data were included in the analysis, significant factors were maximum diameter of liver metastases
(≥ 3.9 cm; HR: 3.1), control of LMBC during follow-up (HR: 0.29), and objective response as best overall response
(HR: 0.21). Neither the presence of any extrahepatic metastases nor presence of bone metastases only had a
significant survival impact. Median OS was 38.7 vs. 16.1 months in patients with metastases < vs. ≥ 3.9 cm, 36.6 vs.
10.2 months for patients having objective response vs. stable/progressive disease, and 38.5 vs. 14.2 months for
patients having controlled vs. non-controlled disease at follow-up.
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Conclusion: Local control of LMBC confers a survival benefit and local interventional treatment for LMBC should be
studied in a randomized trial. Patients with small metastases and limited history of systemic LMBC treatment are
most likely to benefit from local approaches. Limited extrahepatic disease should not lead to exclusion from a
randomized study and should not be a contraindication for local LMBC treatment as long as no randomized data
are available.
Keywords: Liver metastases, Breast cancer, Oligometastases, Locally ablative therapy, Liver surgeryBackground
In the last two decades, the notion that formation of me-
tastases of any malignant tumor indicates systemic
spread of the disease and precludes benefit from local
tumor treatment has been challenged by the observation
that some patients remain disease-free after removal of
their primary tumor and all visible metastatic lesions, in-
dicating cure. As a result, surgical or locally ablative
treatment of metastatic lesions is now an accepted, po-
tentially curative modality in a variety of cancers for pa-
tients with limited metastatic burden (e.g., colorectal,
renal cell, and non small-cell lung cancer) and has been
integrated into treatment guidelines [1–3]. More re-
cently, however, the distinction between “curable” and
“non-curable” cancer has become less clear as some pa-
tients may continuously demonstrate controllable dis-
ease for many years and eventually die from causes
unrelated to their cancer. The propensity of a cancer to
develop rapid dissemination has been referred to as the
disease’s biology; however, it is likely that a complex pat-
tern of interaction between the tumor cells and the host
organism rather than specific properties of the tumor
alone determine the metastatic potential [4]. These ob-
servations have led to the concept of a distinct “oligome-
tastatic” disease state which incorporates patients who
may derive benefit from local treatment (even repeat-
edly) despite the impossibility to achieve true cure [5, 6].
It is unknown if an oligometastatic subpopulation ex-
ists among patients with metastatic breast cancer
(MBC). Generally, MBC is regarded as a systemic dis-
ease and these patients, in line with current European
and American treatment guidelines which essentially re-
serve locally ablative or surgical treatment to lesions that
are symptomatic or prone to cause local complications
[7, 8], are mostly offered palliative systemic treatment
regardless of their metastatic burden. This is particularly
true for liver metastases (LMBC) that typically occur late
in the course of breast cancer and are uncommon in the
absence of extrahepatic disease [9, 10]. Despite this,
there are a number of retrospective, non-randomized re-
ports demonstrating superior survival in patients under-
going liver resection for LMBC [11–15] compared to
patients receiving systemic treatment alone, with surgi-
cally treated patients achieving median survival of up to5 years and 5 year overall survival of up to 60 %, whereas
median survival in MBC patients treated with systemic
therapy only is approximately 24 months and only 5-10 %
are alive at 5 years [16, 17]. Survival figures reported for
patients treated with locally ablative modalities (radiofre-
quency ablation (RFA) or interstitial CT-guided brachy-
therapy (BT)) are generally lower, probably in part owing
to a selection bias. However, they still compare favorably
to systemic treatment alone, demonstrating some benefit
from local control of liver metastases in a disease that is
assumed to be systemic by nature [18–22]. This is further
complemented by the observation that, in chemorefrac-
tory patients not amenable to surgical or locally ablative
treatment, encouraging survival was observed with locore-
gional intrahepatic therapies (90Y radioembolization (RE)
or intrahepatic chemotherapy) [23, 24].
As currently available data do not allow to determine
if improved survival in patients undergoing locoregional
therapy represents a true treatment benefit or must be
regarded as an expression of favorable disease biology,
with patients demonstrating relatively indolent disease
preferably being selected for local treatment, it has
repeatedly been suggested that these treatments be evalu-
ated within a randomized trial comparing the combination
of local and systemic therapy to systemic therapy alone.
The exploratory data we present here is intended to help
modelling such study concepts by identifying prognostic
factors in a cohort of LMBC patients both with and with-
out extrahepatic disease who were not amenable to radical
surgery and received locally ablative (RFA or BT) or locor-
egional intrahepatic (RE) treatment either once or in com-
bination as part of sequential treatment decisions.
Methods
Study design
This retrospective study explores prospectively collected
data from patients with LMBC who were referred to our
department for local interventional treatment of liver
metastases between 2006 and 2010. The local ethics
committee (Ethik-Kommission der Otto-von-Guericke-
Universität in Magdeburg) was informed about the ana-
lyses, an approval was waived due to the retrospective
nature of the study. Written informed consent for
anonymized analysis of disease- and treatment-related
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patients.
Patients undergoing either radiofrequency ablation
(RFA), interstitial catheter-based radiotherapy (BT), or
90Y Radioembolization (RE) for LMBC were included if:
(i) imaging follow-up was available (computed tomog-
raphy (CT) or magnetic resonance imaging (MRI), every
2-4 months), (ii) clinical follow-up data (including la-
boratory analyses) were available (every 2-4 months),
(iii) a written informed consent for anonymized patient
data analysis was available, (iv) no other active cancer
was known.Patient characteristics
59 patients (58 female, 1 male, mean age 57.4 years,
range 32-80) were included in this analysis. Selection of
patients for local interventional treatment was based on
lack of further chemotherapeutic options (progression of
LMBC on all standard chemotherapeutic protocols or
patient refusal of further chemotherapy) as well as surgi-
cal non-resectability of all visible lesions (either technic-
ally or due to impaired patient tolerance for major liver
surgery). Patients had to have liver-predominant disease;
however, limited extrahepatic disease that was stable
under systemic treatment or amenable to local ablation
was allowed.
The median interval from diagnosis of LMBC to presen-
tation for interventional treatment was 22 (1-294) months.Table 1 Baseline Characteristics (59 patients)
Sex (f/m)
Mean age (y, range)
Age≤ 60y
Hormone receptor positive
Her2 neu positive (triple)
Grading (1/2/3/ not available)
Median time from first BC diagnosis to diagnosis of liver metastases (mo, ran
Median time from diagnosis of liver metastases to first interventional treatme
Mean number of liver metastases (n, range)
Mean maximum diameter of liver metastases (cm, range)
Mean liver volume (mL, range)
Mean volume of liver metastases (mL, range)





Lymphatic nodes (others than axillary)
PeritoneumTumors were hormone-receptor positive in 49 of 59
patients and Her2-neu positive in 20 of 59 patients.
Differentiation of liver metastases was graded as G1 (4 pa-
tients), G2 (26 patients), or G3 (21 patients). For 8 patients
no information on tumor differentiation was available.
At presentation for interventional treatment of LMBC,
the mean intrahepatic tumor load (mean cumulative vol-
ume of all liver metastases relative to total liver volume)
was 8.2 % (range 0.1–51.4). Mean number of liver me-
tastases was 13 (range 1-88). The diameter of the largest
liver lesion ranged from 1-14 cm (mean 4.9 cm). The
mean cumulative volume of the liver metastases was
129.6 mL (range 0.5-976), and mean total liver volume
was 1445 mL (range 801-2202).
54 of 59 patients had a history of 1-8 (median 2) lines
of systemic chemotherapy (without hormones) for their
breast cancer prior to presentation for interventional
treatment of LMBC. Bisphosphonates had been applied
in 24 patients. Surgery and external beam radiation for
breast cancer metastases had been performed in 19 and
20 patients, respectively.
29 of 59 patients had evidence of limited extrahepatic
disease at the time of interventional LMBC treatment
(bone metastases only, 19/59 patients; extrahepatic disease
other than bone metastases, 5/59 patients; extrahepatic
disease other than bone metastases and bone metastases,
5/59 patients).
Patient and treatment characteristics are summarized
in Tables 1 and 2.58/1
57.4 (32 - 80)
63 % (n = 37)
83 % (n = 49)
34 % (n = 20)
7 % (n = 4)/ 44 % (n = 26)/36 % (n = 21)/13 % (n = 8)
ge) 45 (0 – 335.4)
nt (mo, range) 22 (1 - 294)
13 (1 - 88)
4.9 (1 - 14)
1445 (801 - 2202)
129.6 (0.5 - 976)
8.2 (0.1 - 51.4)






Table 2 Treatment characteristics (59 patients)
Chemotherapy prior to interventional LMBC treatment (without hormones) 92 % (n = 54)
median number of applied lines (range) 2 (0 - 8)
Local treatment of breast cancer metastases prior to interventional LMBC treatment, overall 68 % (n = 40)
surgery (for metastasis)a n = 19
radiotherapya n = 20
Bisphophonates prior to interventional LMBC treatment n = 24
Concomitant or subsequent breast cancer therapy (after initiation of interventional LMBC treatment), overall 86 % (n = 51)
chemotherapya n = 40
hormonesa n = 22
surgerya n = 7
radiotherapya n = 14
Total number of interventional procedures for LMBCa n = 97
interstitial brachytherapy (BT) n = 68
radioembolization (RE) n = 34
radiofrequency ablation (RFA) n = 5
Number of interventional procedures per patient (1/2/3/4/5/6/7) (n) (37/13/5/0/2/1/1)
First treatment per patient (BT/RE/RFA/combination) (n) (29/22/3/5)
Treatment modalities per patient (first and all subsequent procedures)
RE only n = 17
BT only n = 25
RFA only n = 1
BT and RE n = 12
BT and RFA n = 3
RE and RFA n = 1
amore than one treatment/site per patient possible
Seidensticker et al. BMC Cancer  (2015) 15:517 Page 4 of 12Locally ablative therapies
In general, BT or RFA was performed in case of no more
than five hepatic metastases. RFA was preferred in pa-
tients with a maximum lesion diameter of 3 cm whereas
BT was performed for lesions exceeding this limit and
for lesions under 3 cm with an unfavorable location for
RFA (i.e., close proximity to the liver hilum or other
heat-vulnerable structures).
BT and RFA were performed under conscious sedation
and analgesia using midazolam and fentanyl under
continuous surveillance of vital parameters.
Image guided interstitial brachytherapy (BT)
The technique has been described previously [25].
Briefly, the placement of the introducer sheaths (6 F in
size) with the brachytherapy applicators inside was per-
formed under CT-fluoroscopy using Seldinger tech-
nique. For treatment planning purposes, a contrast
enhanced CT of the liver was acquired. According to the
defined course of the catheters, the clinical target vol-
ume and the predefined minimum dose at the tumor
margin (15 Gy, delivered as a single fraction), theplanning software (Oncentra, Nucletron, Veenendaal,
The Netherlands) calculated a dosimetry and the dwell
of the Iridium-192 source inside the brachytherapy
catheters, respectively. The high-dose-rate afterloading
system (Microselectron, Nucletron, Veenendaal, The
Netherlands) employed an Iridium-192 source with a
nominal activity of 10 Ci..
Radiofrequency ablation (RFA)
All RFA procedures were performed using multitined ex-
pandable electrodes (RITA Starburst; Angiodynamics,
Latham, USA) that were placed under CT or MR
fluoroscopy guidance. The RFA procedure was conducted
according to the manufacturer’s recommendations. To
control the achieved coagulation zone instantaneously
after completing the procedure, a postprocedural con-
trast-enhanced CT scan (or a fat saturated T2-weighted
spinecho sequence in case of conduction under MRI guid-
ance) with the electrode still in place was performed.
If needed, the electrode was repositioned to achieve a
volume large enough to cover the entire metastasis
including a safety margin.
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Radioembolization (RE)
In general, RE was performed if the number of hepatic
metastases exceeded five. RE was performed employing
Yttrium-90 resin microspheres (SIR-Spheres®, Sirtex
Medical, Lane Cove, Australia). Treatment including
pre-procedural diagnostic work-up was performed
according to standard algorithm (detailed description in
[26]). The activity of 90Y resin microspheres was calcu-
lated by the body surface area (BSA) method. 90Y resin
microspheres were delivered selectively into the hepatic
arteries (using a transfemoral approach) sequentially
with an interval of 4-6 weeks between the treatments of
each liver lobe (if a bilobar treatment was necessary). All
patients received proton pump inhibitors (pantoprazole,
20 mg daily), low dose prednisolone (5 mg daily), and
ursodeoxycholic acid (500 mg daily) for 8 weeks to
ameliorate the effect of possibly migrated spheres in the




The following interventional procedures were per-
formed: BT only (29 patients), RFA only (3 patients), RE
only (22 patients). 5 Patients had localized disease in one
liver lobe accompanied by multilocular metastases in the
contralateral lobe and were treated with both unilateral
RE and RFA or BT of the solitary contralateral lesions.
22 patients were re-treated for progressive disease fol-
lowing the first interventional procedure (see Table 2).
Further treatment
Forty patients received subsequent chemotherapy and 22
patients received hormonal therapy following interven-
tional LMBC treatment. Surgery and external beam
radiotherapy for localized extrahepatic disease were per-
formed in 7 and 14 patients, respectively. For detailed
information see Table 2.
Imaging, volumetry and response analysis
For all patients a baseline Gd-EOB-DTPA (Primovist,
Bayer Healthcare, Leverkusen, Germany, 0.025 mmol/
kg/bodyweight) enhanced MRI of the liver was available.
Baseline MRI (hepatobiliary phase T1- weighted im-
aging, 5 mm slice thickness) was used for volumetry of
the liver and tumor volume as well as for measurement
of the tumor diameters using the image processing soft-
ware Osirix (Antoine Rosset, 2003-2011).
Follow-up imaging consisted of either MRI of the liver
or CT of the abdomen (with or without thorax) every 2-
4 months. MRI (1.5 Tesla system, Achieva 1.5 T, Philips,
Best, The Netherlands) of the liver was conducted using
Gd-EOB-DTPA as i.v. contrast agent. For responseanalysis hepatobiliary phase imaging (T1-weighted im-
aging, 5 mm slice thickness) was used. In case of incon-
clusiveness, other sequences (contrast dynamic, T2-
weighted imaging) were taken into account. CT (multi-
slice CT, either 16 (Toshiba Aquilion, Toshiba Medical,
Tokyo, Japan) or 64 (Siemens Definition AS, Erlangen,
Germany) row detector system) was conducted using
90 mL iodinated contrast media (Imeron 300, Iomeprol,
Bracco, Princeton, USA) with a reconstructed slice
thickness of 5 mm. For response analysis, venous phase
imaging was used.
Response analysis according to RECIST 1.0 was per-
formed separately for the liver only and overall. Analyses
of response to treatment are based on best response re-
corded during follow-up.
As an additional efficacy descriptor beyond RECIST,
control of LMBC by interventional treatment during fol-
low-up was used, with patients demonstrating either
overall objective response, stable disease, or limited dis-
ease progression amenable to repeat local ablation being
regarded as having controlled disease. Disease progres-
sion not amenable to local intervention was defined as
non-controlled.Toxicity analysis
All patients underwent standard clinical and laboratory
examination including liver-related parameters at first
presentation and during follow up after interventional
treatment. The Common Terminology Criteria for
Adverse Events (CTCAE) version 4.02 (National Cancer
Institute, USA) were used for toxicity assessments of
laboratory values and clinical findings.
Statistics
Statistical analysis was performed using SPSS (SPSS 21,
IBM, Chicago, Il, USA). Descriptive analysis of patient
characteristics and findings was performed with continu-
ous variables displayed as mean or median with standard
deviation or range and frequency data displayed as
counts.
Survival (from first diagnosis, first diagnosis of liver
metastases, first interventional treatment of LMBC) was
estimated according to the Kaplan-Meier method.
Possible factors influencing survival were included in a
univariate Cox model. Continuous variables were
dichotomized according to a ROC analysis using survival
(longer vs. shorter than median overall survival) as the
target variable. Optimal cut-off was determined according
to the Youden index (see Additional file 1: Table S1).
Interactions of variables found to have significant in-
fluence on survival in the univariate analysis were eval-
uated by the Chi-square test/Fisher’s exact test (see
Additional file 2: Table S2). In case of interactions,
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iate Cox model or the more practicable variable was
chosen. To test the independent impact of each con-
founder identified at univariate analysis on survival, multi-
variate Cox models were created including all variables
that were unevenly distributed between the groups of pa-
tients with shorter vs. longer than median survival and did
not show significant interaction. This analysis was first
performed excluding parameters that were not available
prior to treatment and then repeated using all parameters
(including those available at follow-up only). Additionally,
due to interaction of these variables, separate models were
created to analyze the survival impact of either overall ex-
trahepatic disease or bone metastases as the sole extrahe-
patic tumor manifestation.
Factors found to have an independent impact on sur-
vival in the multivariate model were used as stratifying
variables in a Kaplan-Meier analysis of survival after first
interventional LMBC treatment. The log rank test was
used for survival comparison.
A p < 0.05 was considered statistically significant.
Results
Median overall survival from first interventional treat-
ment of LMBC was 21.9 months (95 % CI: 11.1-32.6),
from first diagnosis of liver metastases, 56.3 months
(44.5-67.9), and from first diagnosis of breast cancer,
127.9 months (87.1-168.7) (Table 3).
The ROC analysis used to dichotomize continuous
variables with respect to median overall survival yielded
the following significant results: number of liver metas-
tases (optimal cut-off: </≥ 6 lesions), maximum diameter
of liver metastases (</≥ 3.9 cm), volume of liver metasta-
ses (</≥ 27.9 mL), intrahepatic tumor load (</≥ 2 %),
liver volume (</≥ 1376 mL), number of previous lines of




from first diagnosis 127.9
from first diagnosis liver metastases 56.3
from first interventional treatment 21.9
Maximum diameter of liver metastases (≥ vs. < 3.9 cm) 16.1
Best response overall (OR, RECIST)
OR (CR + PR) (n = 37) vs. PD + SD (n = 22) 36.6
Disease controlled during follow-up (yes/no)b 38.5
Survival (from first diagnosis, first diagnosis of liver metastases, first interventional t
found to have an independent impact on survival in the multivariate model (Table
first interventional LMBC treatment. The log rank test was used for survival compar
aAddressing overall survival data and significant influencing factors from multivaria
bPatients demonstrating either overall objective response, stable disease, or limited
having controlled disease. Disease progression not amenable to local intervention wCEA (</≥ 6.2U/mL) (see Additional file 1: Table S1).
Dichotomized variables were used for further analyses.
Although the ROC analysis was unable to dichotomize
time from first breast cancer diagnosis to diagnosis of
liver metastases, this variable was still considered a
possible influencing factor for further analyses with a
cut-off based on data reported in the literature
(<2 years vs. ≥ 2 years; [27]).
Univariate Cox regression regarding overall survival
from first interventional LMBC treatment of the LMBC
yielded type of initial local treatment (BT/RFA vs. RE),
presence of extrahepatic metastases, presence of bone
metastases only, number of liver metastases, maximum
diameter of liver metastases, volume of liver metastases,
tumor load, liver volume, number of lines of chemotherapy
applied prior to interventional LMBC treatment, CA 15-3,
CEA, best response during follow-up (overall), best re-
sponse during follow-up (liver only), and control of LMBC
by interventional treatment during follow-up (according to
the definition given in the methods section) as factors with
a significant survival impact (Table 4). These variables were
then tested for inter-variable interaction (see Additional file
2: Table S2) and the following non-interacting variables
were extracted for inclusion into the multivariate Cox
models: presence of extrahepatic metastases (and presence
of bone metastases only, separate model), liver volume,
maximum diameter of liver metastases, number of liver
metastases, number of lines of chemotherapy applied prior
to interventional LMBC treatment, control of LMBC by
interventional treatment during follow-up, and best overall
response to interventional treatment during follow-up.
When only factors available at treatment initiation were in-
cluded in the analysis, only maximum diameter of liver
metastases (≥ 3.9 cm; HR: 3.1), liver volume (≥ 1376 mL;
HR: 2.3), and history of prior chemotherapy (≥ 3 lines of




38.7 9.8 - 22.5 19.6 - 57.8 0.001
10.2 26.4 - 46.7 6.1 - 14.3 < 0.001
14.2 27.1 - 39.7 9.4 - 18.9 0.002
reatment of LMBC) estimated according to the Kaplan-Meier method. Factors
5) were used as stratifying variables in a Kaplan-Meier analysis of survival after
ison
te cox regression
disease progression amenable to repeat local ablation were regarded as
as defined as non-controlled
Table 4 Univariate Cox Regression for Survival
Variable Hazard ratio 95 % CI p-value
Age 0.99 0.97 - 1.03 0.836
Age (>60y) 0.51 0.24 - 1.11 0.089
Hepatic progression in FU (yes) 0.8 0.37 - 1.73 0.566
Systemic progression in FU (yes) 1.57 0.78 - 3.17 0.209
Under local control in FU (yes) 0.31 0.14 - 0.68 0.004
Her2 neu (pos) 1.22 0.59 - 2.53 0.588
Hormone receptor (pos) 0.96 0.41 - 2.24 0.926
Grading (1-3) 0.93 0.5 - 1.73 0.826
Other prior therapies for metastastes (yes) 1.99 0.89 - 4.43 0.094
Extrahepatic metastases (yes) 2.86 1.39 - 5.87 0.004
bones only 3.01 1.49 - 6.08 0.002
First local treatment
Brachytherapy (BT) or RFA 0.28 0.13 - 0.59 0.001
Radioembolization (RE) 3.31 1.57 - 6.98 0.002
Combination RE/BT or RE/RFA 1.14 0.40 - 3.26 0.813
Best response hepatic (OR, RECIST) 0.37 0.17 - 0.79 0.01
Best response overall (OR, RECIST) 0.15 0.07 - 0.34 < 0.001
Clinical and laboratory grade 3/4 toxicities (yes) 1.83 0.78 - 4.31 0.168
Number of liver metastases (≥ 6) 2.08 1.01 - 4.31 0.048
Maximum diameter of liver metastases (≥ 3.9 cm) 3.43 1.57 - 7.52 0.002
Liver volume (≥ 1376 mL) 2.27 1.11 - 4.64 0.024
Volume of liver metastases (≥ 27.9 mL) 4.33 1.91 - 9.79 < 0.001
Tumor load (≥ 2 %) 5.6 2.37 - 13.23 < 0.001
Lines of chemotherapy (≥ 3) 3.17 1.55 - 6.49 0.002
CA 15-3 (≥ 62.6U/mL) 2.42 1.10 - 5.36 0.029
CEA (≥ 6.2U/mL) 3.36 1.58 - 7.15 0.002
Time from first diagnosis to liver metastases (≥ 2y) 0.79 0.40 - 1.56 0.492
Concomitant or subsequent therapies for breast cancer metastases (yes) 0.43 0.16 - 1.16 0.094
Possible factors influencing survival were included in a univariate Cox model. Continuous variables were dichotomized according to a ROC analysis (see Additional
file 1: Table S1)
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those available at follow-up only, only maximum diameter
of liver metastases (≥ 3.9 cm; HR: 3.1), control of LMBC
by interventional treatment during follow-up (HR: 0.29),
and objective response as best overall response during
follow-up (HR: 0.21) demonstrated a significant influence
on survival (Table 5b). Neither the presence of any extrahe-
patic metastases nor presence of bone metastases only had
a significant impact on survival in any of the models
(Table 5a and b).
Overall survival estimates stratified for the maximum
diameter of liver metastases (</≥ 3.9 cm) were 38.7 vs.
16.1 months (p = 0.001), for best overall response during
follow-up (objective response vs. SD and PD), 36.6 vs.
10.2 months (p < 0.001), and for control of LMBC byinterventional treatment during follow-up (yes vs. no),
38.5 vs. 14.2 months (p = 0.002) (Table 3).
After interventional treatment of LMBC, 9 grade 3
and no grade 4 toxicities were recorded. This included
elevation of alanine aminotransferase (1 patient), eleva-
tion of alkaline phosphatase and reduction of albumin (1
patient), liver decompensation (defined as ascites unre-
lated to disease progression; 5 patients), and i.v. port in-
fection (1 patient). All reported toxicities occurred after
radioembolization. Patients developing any grade 3 tox-
icity following treatment had a tendency towards de-
creased survival (median survival, 8.2 vs. 14.2 months
with vs. without toxicity in patients receiving RE at any
time during their treatment sequence); however, this was
not significant (p = 0.234).
Table 5 Multivariate Cox Regression for Survival
a. Multivariate Cox Regression for Survival, Factors available at treatment initiation only
Variable set Hazard ratio 95 % CI p-value
Extrahepatic metastases (yes) 2.13 0.97 - 4.64 0.058
Liver volume (≥ 1376 mL) 2.25 1.01 - 5.02 0.047
Maximum diameter of liver metastases (≥ 3.9 cm) 3.12 1.39 - 7.02 0.006
Number of liver metastases (≥ 6) 1.48 0.69 - 3.14 0.312
Lines of chemotherapy (≥ 3) 2.48 1.15 - 5.36 0.021
Bone metastases only (yes) 1.56 0.70 - 3.47 0.279
Liver volume (≥ 1376 mL) 2.01 0.93 - 4.36 0.076
Maximum diameter of liver metastases (≥ 3.9 cm) 3.1 1.37 - 7.02 0.007
Number of liver metastases (≥ 6) 1.51 0.72 - 3.20 0.278
Lines of chemotherapy (≥ 3) 2.6 1.14 - 5.92 0.023
b. Multivariate Cox Regression for Survival, All Factors (Pre- and Posttherapeutic)
Variable set Hazard ratio 95 % CI p-value
Extrahepatic metastases (yes) 1.05 0.43 - 2.58 0.92
Liver volume (≥ 1376 mL) 2.17 0.90 - 5.22 0.084
Maximum diameter of liver metastases (≥ 3.9 cm) 3.1 1.31 - 7.36 0.01
Number of liver metastases (≥ 6) 1.13 0.49 - 2.59 0.782
Lines of chemotherapy (≥ 3) 1.81 0.83 - 3.97 0.138
Under local control in FU (yes) 0.29 0.11 - 0.73 0.009
Best response overall (OR, RECIST) 0.21 0.08 - 0.57 0.002
Bone metastases only (yes) 1.06 0.46 - 2.44 0.89
Liver volume (≥ 1376 mL) 2.16 0.92 - 5.03 0.075
Maximum diameter of liver metastases (≥ 3.9 cm) 3.05 1.22 - 7.61 0.017
Number of liver metastases (≥ 6) 1.12 0.48 - 2.59 0.796
Lines of chemotherapy (≥ 3) 1.8 0.80 - 4.01 0.154
Under local control in FU (yes) 0.29 0.12 - 0.70 0.006
Best response overall (OR, RECIST) 0.21 0.08 - 0.52 0.001
Multivariate cox models were created on the basis of significant and non-interacting factors from univariate analysis with one model exclusively analyzing factors
available prior to treatment (5 a.) and a separate model including all factors including those available at follow-up only (5 b.). Additionally, due to interaction of
these variables, separate models were created to analyze the survival impact of either overall extrahepatic disease or bone metastases as the sole extrahepatic
tumor manifestation
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In the past, scientific workup of surgical treatment for
patients with metastatic cancers has been hampered by
the fact that surgery used to carry substantial risks
which were considered to be non-justified in a disease
that is unlikely to be cured. Nonetheless, with the con-
tinuing improvement of perioperative outcomes in liver
surgery, there is now an increasing role for liver resec-
tion as part of a multidisciplinary treatment concept in
many cancers, even outside of a curative approach [28,
29]. Minimally invasive local treatment modalities have
been developed to further reduce periprocedural risks.
Recent data referring to a variety of techniques demon-
strates encouraging results regarding local tumor clear-
ance, making them particularly attractive in patients inwhom a more radical approach associated with higher
morbidity may not be acceptable because a survival
benefit cannot be reliably predicted. Among these treat-
ments, RFA is the most widely accepted modality and is
regularly used to ablate liver tumors of limited number
and size (usually <3-5 cm) in a suitable location (i.e.,
outside the immediate vicinity of large vessels to
minimize the heat-sink effect, or at some distance from
the hepatic bifurcation) [30]. Image-guided, catheter-
based, interstitial brachytherapy is employed by an in-
creasing number of centers since it avoids the tumor size
limitation applicable for RFA [20, 25, 31]. Finally, RE
using 90Y-labelled glass or resin microspheres is able to
target multifocal lesions not amenable to RFA or inter-
stitial BT due to its inherent locoregional effects. RE has
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and metastatic liver tumors [32].
No data is currently available on the outcome of sin-
gle, combined or sequential use of such locally and
locoregionally active devices. For the cohort described
herein, treatment decisions were generally based on 2
dominant terms:
a) a therapeutic algorithm mirroring the individual
patient situation, i.e., all disease except for
(controlled) bone metastases was amenable to
treatment using a minimally invasive technique;
systemic chemotherapy was either not effective, not
further applicable due to toxicity or refused by the
patient.
b) the selection of the appropriate device followed the
technical considerations described above; i.e., RFA
for patients with up to 3 tumors up to 3 cm in
diameter (if not adjacent to main portal vein or
hepatic bifurcation); BT for patients with up to 5
tumors any size in any location; RE for diffuse
disease with up to 50 % tumor load.
Due to its liberal inclusion criteria with no upper limit
to the number and size of liver metastases, extensive
prior chemotherapy in almost all patients, and inclusion
of patients with controlled extrahepatic disease (both
sceletal and extrasceletal), the present study represents a
negatively selected cohort of patients. In this dismal
patient selection with LMBC diagnosed almost 2 years
(median 22 months) prior to presentation for local treat-
ment, the observed median overall survival of 21.9 months
compares favorably with literature results on patients with
LMBC undergoing systemic treatments only [33]. Our pa-
tient cohort recruited between 2006 and 2010 did not
benefit of advances in systemic treatments that were re-
cently reported for the use of nab-Paclitaxel in patients
with metastatic breast cancer [34], with approx. 80 % of
the patients in that study having visceral metastases
whereas the proportion of hepatic metastases (that are
considered to confer a particularly poor prognosis [35])
was not specified. Hence, our results must be compared
to studies employing anthracycline, taxanes or cyclophos-
phamide. Data available refers to first line patients (in con-
trast to our cohort in a salvage situation), and median
overall survival ranged from 22.7 to 27.1 months in pa-
tients with liver metastases only and from 14-16.8 months
in patients with liver-dominant and limited extrahepatic
disease [10, 9, 36]. The beneficial effect of a local treat-
ment approach is further complemented by the observa-
tion that local control of the liver metastases and objective
response to locoregional treatment at follow-up were
found to be the strongest factors indicating prolonged sur-
vival at multivariable analysis in our study (HR of 0.29 and0.21, respectively). Thus, in contrast to the view held by
some investigators that local control of liver metastases in
breast cancer has no survival impact due to the general-
ized nature of the disease [37], our results (in line with
other published research [38]) are rather suggestive of the
existence of an oligometastatic subpopulation in LMBC
patients whose prognosis is determined by the visible le-
sions rather than subclinical tumor dissemination which
will cause rapid systemic progression regardless of local
disease control. The observation that most patients devel-
oping recurrence following resection of LMBC have the
liver as their first site of recurrence further underscores
this view [39, 40].
There are currently no methods to reliably identify the
oligometastatic subpopulation which may benefit from
local surgical or image-guided treatment approaches. In
the absence of established molecular biomarkers, the
selection of metastatic breast cancer patients who are
most likely to derive benefit relies on retrospective iden-
tification of prognostic factors in patients receiving these
therapies. In published studies, patient characteristics
most often reported to be associated with prolonged sur-
vival include long disease-free interval between the treat-
ment of the primary cancer and the diagnosis of liver
metastases [40, 41], small size and/or low number of
liver metastases [14, 15, 21, 42], well-differentiated histo-
pathology [14], and response to pre-interventional or
preoperative chemotherapy [43]. In some studies, pa-
tients demonstrating extrahepatic disease were generally
excluded from local or locoregional treatment [14, 42,
44]. In the studies that did include patients with tumor
spread beyond the liver, presence of extrahepatic disease
was identified as a poor prognostic factor by some [12,
13, 45] but not all investigators [21, 43]. In the study by
Jakobs et al. [22], presence of extrahepatic disease in pa-
tients undergoing RFA of liver metastases was associated
with poor prognosis; however, this did not apply to pa-
tients who had bone metastases as their only extrahe-
patic tumor site.
Since factors predictive for treatment benefit should
be available before treatment is started, we first analyzed
the survival impact of parameters prior to treatment
only. Of these parameters, only large liver volume,
tumor diameter of ≥ 3.9 cm, and at least 3 lines of
chemotherapy prior to local treatment were associated
with poor prognosis. Presence of extrahepatic disease
showed a tendency towards a negative prognostic impact
(p = 0.058) when only factors known prior to the thera-
peutic decision were included. The negative effect al-
most vanished if extrahepatic disease was limited to
bone metastases only. To evaluate the survival benefit
conferred by locally ablative treatment, parameters re-
lated to treatment outcome that were available at follow-
up only were entered into a subsequent analysis.
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treatment response were the strongest predictors of
good outcome in this setting, whereas neither the pres-
ence of any extrahepatic disease, nor evidence of bone
metastases as the only extrahepatic tumor site preserved
their tendency towards a negative prognostic impact..
Interestingly, the impact of prior chemotherapy was also
no longer significant, indicating that even heavily pre-
treated patients may derive benefit from locoregional
treatment modalities if local control of the liver lesions
is achieved.
The treatments used in our study appeared to be gen-
erally safe, with no grade 4 toxicities observed and only
few grade 3 toxicities occurring exclusively among pa-
tients treated with RE. Although a tendency towards de-
creased survival in patients developing grade 3 toxicity
was noted, this was not significant. A larger analysis is
required to reliably establish the relationship between
treatment toxicity and outcome, and to determine how
toxicities occurring after locally ablative treatment
impact patient’s tolerance for further antineoplastic
therapy.
In summary, our results indicate that patients most
likely to derive benefit from local or locoregional LMBC
treatment are those with a largest tumor diameter of <
4 cm and only limited history of systemic chemotherapy
prior to treatment. According to our data, patients with
controlled extrahepatic disease, and specifically patients
with bone metastases as the only extrahepatic site, may
be considered for local ablation. We postulate that this
is the patient population that should be selected for fu-
ture trial concepts designed to compare local tumor
treatment plus systemic chemotherapy with standard
chemotherapy alone.
Our study has several limitations. First, we have no
sound explanation for the finding that liver volume
≥1376 ml was identified as an independent poor prog-
nostic factor. Because liver volume included the volume
of any intrahepatic tumor lesions, one might suspect
that this was simply an expression of high tumor load
being responsible for increased liver volume, thereby
impairing survival. However, there was no correlation
between liver volume and the volume of liver metastases
(see Additional file 2: Table S2). For patients undergoing
RE, a possible explanation could be that dose calculation
according to the BSA method as in our study may lead
to relative underdosing of 90Y in patients whose liver
volume to BSA ratio is elevated compared to the average
population. Using our data, we were unable to test this
hypothesis and any attempt at providing an explanation
for this finding must remain speculative. Second, our se-
lection of patients based on the criterion “no uncon-
trolled extrahepatic disease” was somewhat subjective.
This represents clinical practice at our institution as wellas in many other centers. It may be appropriate as long
as neither a broadly accepted definition of “controllable
disease” nor treatment guidelines exist. However, for a
future prospective trial a clear definition of what extent
of extrahepatic disease is acceptable must be adopted.
According to our data, this should clearly include pa-
tients with bone metastases only. For extrasceletal me-
tastases, a possible threshold could be sustained disease
stabilization for at least 12 months prior to local treat-
ment as in the study by Hoffmann et al. [40]. Third, with
patients included in our study who underwent RFA,
interstitial brachytherapy, and RE, a very heterogeneous
spectrum of treatment modalities and tumor distribution
within the liver was analyzed. Thermal (RFA) vs. non-
thermal (BT and RE) treatments are based on different
working principles, as are high-dose (BT) vs. low-dose
(RE) radiation therapy. If high-dose, catheter-based
brachytherapy or low-dose, microsphere-based radioem-
bolization is more effective in terms of response as well
as recurrence rate and survival will be an area of high
interest for larger, future analyses. The aim of our study,
however, was to obtain information on the general benefit
of liver-directed local treatment in metastatic breast
cancer and to identify predictive and prognostic factors to
help modelling future research strategies. All of the
treatments studied exclusively target intrahepatic disease;
hence, we considered it appropriate for our exploratory
purposes to perform a joint analysis of the results obtained
with all of these treatments.Conclusions
In conclusion, our results confirm that patients with
hepatic metastases from breast cancer, despite being
incurable in most cases, may have favorable survival out-
comes from locoregional treatment of their liver disease.
The exact role of such therapies must be established in a
randomized trial. Our study supports the assumption
that an “oligometastatic” subgroup exists among patients
with breast cancer metastases and that, as long as no re-
liable biomarkers exist to predict disease behavior, even
limited extrahepatic disease should not automatically
exclude patients from being treated locally.Additional files
Additional file 1: Table S1. ROC Analysis and Cut-off Values. In order
to prepare continuous variables for the Cox model, the according
variables were dichotomized by a ROC analysis using survival (longer vs.
shorter than median overall survival) as the target variable. Optimal cut-off
was determined according to the Youden index. Variables with no
significant cut-off were not used for the cox model, except the variable time
from first breast cancer diagnosis to diagnosis of liver metastases since this
variable was still considered as a possible influencing factor according to
literature (with a cut off <2 years vs. ≥ 2 years).
Seidensticker et al. BMC Cancer  (2015) 15:517 Page 11 of 12Additional file 2: Table S2. Chi-Square Test for Interactions. The
Chi-Square test was used to identify interactions between variables
with influence on survival according to the univariate cox model in
order to build up a robust multivariate cox model without interacting
variables.
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